| 标题 |
[求助补充材料]
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:Lancet Oncology 作者:Yann Vano; Réza Elaidi; Mostefa Bennamoun; Christine Chevreau; Delphine Borchiellini; et al 出版日期:2022-04-04 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)